.Merck & Co.'s TIGIT program has suffered one more drawback. Months after shuttering a stage 3 mo...
.After a year defined by pipeline hairstyles, the variation of its CEO and layoffs, Exscientia will ...
.Cullinan Therapeutics was actually wowed enough with Port BioMed's bispecific invulnerable activato...
.Within this full week's incident of "The Best Pipe," our team are actually diving right into Strong...
.The confetti is still flying coming from Eli Lilly's event commemorating the approval of Alzheimer'...
.Welcome to this week's Chutes & Ladders, our summary of substantial leadership hirings, shooting...
.Adhering to a poor presenting for Lykos Rehabs' MDMA candidate for post-traumatic stress disorder a...
.AN2 Therapies is actually rethinking its own company in response to uninspired midphase data, swear...
.Merck & Co. is paying for $700 million in advance to challenge Amgen in a blood stream cancer ce...
.Along With Gilead Sciences on the verge of an FDA selection for its liver health condition drug sel...